STOPCAP M1, prostate RT, systematic review and aggregate data meta-analysis
Addition of prostate radiotherapy to ADT in men with metastatic, hormone-sensitive prostate cancer: a systematic review and meta-analyses of aggregate data
Does giving radiotherapy to the prostate in addition to hormone therapy improve survival for men with metastatic hormone-sensitive prostate cancer?
What was this study about?
A systematic review and meta-analyses was carried out bringing together trials that looked at whether adding prostate radiotherapy to hormone therapy (androgen deprivation therapy [ADT]), improved survival in men with metastatic hormone-sensitive prostate cancer.
What difference did this study make?
The review found that that for all men, the addition of prostate radiotherapy lengthened the amount of time before the disease spread further but didn’t help men to live longer. It did improve survival for men whose cancer had not spread too much when they were first diagnosed.
Type of study
Who funded the study?
Medical Research Council, UK and Prostate Cancer UK
When did it take place?
This study was published in 2019 and brought together the results of trials that were carried out between 2004 and 2016.
Where did it take place?
This study was done at the MRC Clinical Trials Unit at UCL but brings together the results of two trials from Europe.
Who was included?
This study brought together the results of two trials (2126 patients) that studied the addition of prostate radiotherapy in addition to ADT.